Major Depressive Disorder Market Report 2026

The major depressive disorder market size has grown steadily in recent years. It will grow from $6.26 billion in 2025 to $6.44 billion in 2026 at a compound annual growth rate (CAGR) of 2.9%. The growth in the historic period can be attributed to increasing prevalence of depressive disorders, growing societal awareness of mental health, wider availability of antidepressant medications, expansion of psychiatric care infrastructure, improved diagnostic guidelines for mood disorders.

The major depressive disorder market size is expected to see steady growth in the next few years. It will grow to $7.49 billion in 2030 at a compound annual growth rate (CAGR) of 3.9%. The growth in the forecast period can be attributed to rising mental health burden due to lifestyle stress, increasing adoption of digital mental health platforms, growing demand for personalized depression treatments, expansion of insurance coverage for mental health care, continued innovation in neuromodulation therapies. Major trends in the forecast period include rising adoption of combination therapy approaches, growing demand for non-invasive brain stimulation treatments, increasing awareness and diagnosis of depression, expansion of telepsychiatry and remote mental health care, rising acceptance of novel and rapid-acting antidepressants.

The increase in cases of substance abuse and alcohol abuse is expected to drive the growth of the major depressive disorder market. Substance and alcohol abuse refer to patterns of excessive and harmful use of substances, including alcohol, which can result in negative physical, psychological, and social consequences. These conditions often co-occur with major depressive disorder, and each can exacerbate the other, significantly raising the risk of physical and mental harm. For example, in July 2024, a survey published by the Substance Abuse and Mental Health Services Administration, a US-based department of health and human services, reported that 3.1% of people (8.9 million) misused opioids in 2023, while 21.8% of individuals aged 12 or older used marijuana, making it the most commonly used illicit drug. Additionally, 9.4% of people aged 12 or older vaped nicotine in the past month, up from 8.3% in 2022. Consequently, the rise in cases of substance abuse and alcohol abuse is contributing to the growth of the major depressive disorder market.

Major companies in the major depressive disorder (MDD) market are concentrating on creating innovative solutions, such as prescription digital therapeutics (PDTs), to address the growing need for scalable access to evidence-based psychotherapy, adjunctive treatments for partial responders, and remote, measurement-driven care pathways. Prescription digital therapeutics (PDTs) are software-as-medical-device interventions delivered via prescription that integrate clinically validated therapeutic content, remote engagement and adherence tools, and data collection for clinicians; unlike conventional antidepressant medications or in-person psychotherapy, PDTs offer repeatable, standardized, and remotely supervised behavioral interventions that can complement pharmacotherapy or bridge gaps where provider access is limited. For example, in April 2024, Otsuka Pharmaceutical Co., a Japan-based pharmaceutical company, in collaboration with Click Therapeutics, launched Rejoyn (developed as CT-152), a prescription digital therapeutic approved by the U.S. FDA as an adjunctive treatment for adults with MDD who are on antidepressant medication. Rejoyn is a six-week, smartphone-delivered program centered on clinically validated cognitive-emotional brain-training exercises (the Emotional Faces Memory Task/EFMT) and brief therapeutic lessons designed to improve cognitive control of emotion. The app operates through prescribed delivery, with patients downloading and completing scheduled sessions on their smartphones while clinicians prescribe and monitor usage, and it was evaluated in the MIRAI randomized, sham-controlled trial demonstrating symptom improvement compared to control. Its unique features include a neuromodulatory design targeting neural networks involved in emotion processing, remote personalized reminders to enhance adherence, and regulatory clearance as a medical device rather than a wellness app.

In October 2025, AbbVie Inc., a US-based healthcare and biopharmaceutical company, acquired bretisilocin from Gilgamesh Pharmaceuticals, Inc. for an undisclosed sum. Through this acquisition, AbbVie Inc. aims to enhance and broaden its psychiatry and neuroscience pipeline by incorporating a next-generation, short-acting psychedelic-derived candidate to accelerate development in major depressive disorder. Gilgamesh Pharmaceuticals Inc. is a US-based clinical-stage biotechnology company focused on developing novel psychedelic-derived and psychoplastogen therapies, including bretisilocin, a Phase 2 investigational 5-HT₂A receptor agonist for moderate-to-severe major depressive disorder.

Major companies operating in the major depressive disorder market are Pfizer Inc., Janssen Research and Development LLC, Merck and Co. Inc., Novartis AG, Sanofi-Aventis US LLC, Bristol Myers Squibb Co., AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Biogen Inc., Otsuka Pharmaceuticals Co. Ltd., Forest Laboratories Inc., H. Lundbeck A/S, Richter Gedeon plc, Allergan plc, Neurocrine Biosciences Inc., BlackThorn Therapeutics Inc., Intra-Cellular Therapies Inc., Axsome Therapeutics Inc., Luye Pharma Group, BrainsWay Ltd., Neumora Therapeutics Inc., Chase Therapeutics Corporation, SAGE Therapeutics Inc., Relmada Therapeutics Inc., Fabre-Kramer Pharmaceuticals Inc., Vistagen Therapeutics Inc.

North America was the largest region in the major depressive disorder market in 2025. The regions covered in the major depressive disorder market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the major depressive disorder market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have had a moderate impact on the major depressive disorder market by increasing the cost of imported pharmaceuticals, neuromodulation devices, and diagnostic equipment. These effects are most noticeable in medication and brain stimulation treatment segments, particularly in regions dependent on imported medical technologies such as north america and parts of europe. Higher tariffs can raise treatment costs and slow adoption in cost-sensitive healthcare systems. However, tariffs have also encouraged domestic drug manufacturing and local production of medical devices, supporting long-term supply stability.

The major depressive disorder market research report is one of a series of new reports that provides major depressive disorder market statistics, including major depressive disorder industry global market size, regional shares, competitors with a major depressive disorder market share, detailed major depressive disorder market segments, market trends and opportunities, and any further data you may need to thrive in the major depressive disorder industry. This major depressive disorder market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Major depressive disorder is a mood disorder characterized by a persistent feeling of sadness and loss of interest, which can disrupt daily activities such as sleeping, eating, or working. It goes beyond typical mood changes and can profoundly affect a person's thoughts, emotions, behavior, and physical health. Treatment for major depressive disorder includes various medical interventions aimed at supporting an individual's emotional well-being.

The primary treatments for major depressive disorder include psychotherapy, medications, electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), and other approaches. Psychotherapy involves a trained mental health professional assisting individuals or groups in addressing emotional, psychological, and behavioral challenges. Diagnosis can involve physical examinations, laboratory tests, psychiatric evaluations, the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), and other methods, provided by various end users such as hospitals, clinics, and similar facilities.

The major depressive disorder market consists of revenues earned by entities by providing services such as teletherapy, integrated care, cognitive behavioral therapy, interpersonal therapy, mindfulness-based therapy and residential treatment. The market value includes the value of related goods sold by the service provider or included within the service offering. The major depressive disorder market also includes sales of monoamine oxidase inhibitors, tricyclic antidepressants and mirtazapine. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.